Tracy Marshbanks Sells 38,236 Shares of ANI Pharmaceuticals, Inc. (ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Director Tracy Marshbanks sold 38,236 shares of the firm’s stock in a transaction that occurred on Wednesday, May 16th. The shares were sold at an average price of $62.33, for a total transaction of $2,383,249.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Tracy Marshbanks also recently made the following trade(s):

  • On Thursday, May 10th, Tracy Marshbanks sold 62,431 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $62.07, for a total transaction of $3,875,092.17.
  • On Wednesday, April 18th, Tracy Marshbanks sold 33,200 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $62.09, for a total transaction of $2,061,388.00.
  • On Thursday, March 8th, Tracy Marshbanks sold 15,391 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $63.08, for a total transaction of $970,864.28.
  • On Monday, March 12th, Tracy Marshbanks sold 64,221 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $63.03, for a total transaction of $4,047,849.63.

ANIP stock opened at $64.61 on Friday. The company has a debt-to-equity ratio of 1.11, a quick ratio of 2.75 and a current ratio of 3.62. ANI Pharmaceuticals, Inc. has a twelve month low of $61.99 and a twelve month high of $62.69. The company has a market cap of $738.73 million, a price-to-earnings ratio of 15.22 and a beta of 2.93.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Tuesday, May 8th. The specialty pharmaceutical company reported $1.32 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.04. ANI Pharmaceuticals had a net margin of 0.01% and a return on equity of 27.16%. The company had revenue of $46.48 million for the quarter, compared to analysts’ expectations of $49.93 million. During the same quarter last year, the company earned $0.74 earnings per share. The firm’s revenue for the quarter was up 26.9% on a year-over-year basis. analysts predict that ANI Pharmaceuticals, Inc. will post 5.43 earnings per share for the current year.

A number of hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. raised its holdings in ANI Pharmaceuticals by 1.7% during the first quarter. BlackRock Inc. now owns 1,296,388 shares of the specialty pharmaceutical company’s stock worth $75,478,000 after purchasing an additional 22,037 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in ANI Pharmaceuticals by 2.7% during the first quarter. Dimensional Fund Advisors LP now owns 468,244 shares of the specialty pharmaceutical company’s stock worth $27,261,000 after purchasing an additional 12,427 shares in the last quarter. LSV Asset Management raised its holdings in ANI Pharmaceuticals by 1,113.5% during the first quarter. LSV Asset Management now owns 305,800 shares of the specialty pharmaceutical company’s stock worth $17,803,000 after purchasing an additional 280,600 shares in the last quarter. Deutsche Bank AG raised its holdings in ANI Pharmaceuticals by 7.4% during the fourth quarter. Deutsche Bank AG now owns 159,957 shares of the specialty pharmaceutical company’s stock worth $10,308,000 after purchasing an additional 10,982 shares in the last quarter. Finally, Cortina Asset Management LLC acquired a new stake in ANI Pharmaceuticals during the fourth quarter worth approximately $6,091,000. 58.31% of the stock is currently owned by institutional investors.

Several analysts recently weighed in on ANIP shares. BidaskClub cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, January 24th. TheStreet cut shares of ANI Pharmaceuticals from a “b” rating to a “c+” rating in a report on Tuesday, February 20th. Canaccord Genuity set a $82.00 target price on shares of ANI Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, February 27th. ValuEngine raised shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, March 2nd. Finally, Zacks Investment Research raised shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating and set a $69.00 target price on the stock in a report on Monday. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. ANI Pharmaceuticals has an average rating of “Buy” and a consensus price target of $77.00.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis.

Insider Buying and Selling by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply